Physician profile
Blaine E Jensen
NPI 1346390242
$4,016.07
in general payments reported to CMS, 2019-2025
23 companies · $832 in 2025
The $832 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $677 · 2023: $1,030 · 2024: $1,229 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.50 |
| Education | $210.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,002.08 | 2021-2025 | |
| Abbvie INC. | $590.14 | 2021-2025 | |
| Janssen Biotech, INC. | $444.11 | 2022-2025 | Tremfya, Remicade, Stelara |
| Leo Pharma INC. | $386.94 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $276.94 | 2021-2024 | Taltz, Olumiant |
| Pfizer INC. | $225.09 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $145.36 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $135.87 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $127.21 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $113.10 | 2021-2024 | |
| Incyte Corporation | $94.82 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $75.00 | 2021-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $72.59 | 2022-2024 | Sotyktu |
| Amgen INC. | $68.85 | 2022-2024 | Otezla |
| Mayne Pharma Commercial LLC | $59.63 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $56.83 | 2021-2024 | Bimzelx |
| Krystal Biotech INC | $33.25 | 2024 | Vyjuvek |
| Journey Medical Corporation | $25.95 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.04 | 2022 | |
| Galderma Laboratories, L.P. | $16.73 | 2023 | |
| Biofrontera INC. | $15.08 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.04 | 2023 | Jublia |
| Misonix INC | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blaine Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.